BioLineRx (BLRX) Net Income towards Common Stockholders (2011 - 2025)
BioLineRx's (BLRX) quarterly Net Income towards Common Stockholders came in at -$2.2 million in Q4 2025, up 29.84% year-on-year from -$1.7 million in Q4 2024, and down 128.86% quarter-over-quarter from -$977000.0 in Q3 2025.
BioLineRx (BLRX) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends
BioLineRx's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders rose 29.84% year-over-year to -$2.2 million in Q4 2025; TTM through Dec 2025 was -$2.0 million, a 11.1% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 87.26% from the prior year.
- Net Income towards Common Stockholders fell to -$2.2 million in Q4 2025 per BLRX's latest filing, from -$977000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.1 million in Q1 2025 and bottomed at -$23.1 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$0.01 (2021), against an average of -$1.7 million.
- Across the five-year window, Net Income towards Common Stockholders surged 4539999900.0% in 2024 and sank 533.92% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$0.01 in 2021, then changed by 0.0% to -$0.01 in 2022, then tumbled by 230569999900.0% to -$23.1 million in 2023, then surged by 86.18% to -$3.2 million in 2024, then climbed by 29.84% to -$2.2 million in 2025.
- Per Business Quant, the three latest BLRX Net Income towards Common Stockholders figures stand at -$2.2 million (Q4 2025), -$977000.0 (Q3 2025), and -$3.9 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | BioLineRx | 6.98 Bn | 6.98 Bn | 154,000.00 | -2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.24 Mn |
| Sep 30, 2025 | -977,000.00 |
| Jun 30, 2025 | -3.94 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | -3.19 Mn |
| Jun 30, 2024 | 908,000.00 |
| Dec 31, 2023 | -23.06 Mn |
| Sep 30, 2023 | -0.02 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | -0.01 |
| Sep 30, 2022 | -0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | -0.01 |
| Sep 30, 2021 | -0.01 |
| Jun 30, 2021 | 0.01 |
| Mar 31, 2021 | -0.02 |
| Dec 31, 2020 | -0.04 |
| Sep 30, 2020 | -0.02 |
| Jun 30, 2020 | 0.03 |
| Mar 31, 2020 | -0.04 |